medigraphic.com
Instituto Nacional de Neurología y Neurocirugía

2015, Number 2

<< Back Next >>

Arch Neurocien 2015; 20 (2)

Utility of two biomarkers measured by MRI diffusion tensor for the differential diagnosis between early Parkinson’s disease and atypical parkinsonism

Santana-López JM, Alvarado P, Rodríguez-Violante M, Cervantes-Arriaga A

Language: Spanish
References: 17
Page: 116-121
PDF size: 94.39 Kb.


ABSTRACT

Objective: to determine the usefulness of the quantitative analysis of structural and volumetric changes at the level of the substantia nigra on magnetic resonance studies by fractional anisotropy and mean diffusivity to differentiate between patients with early Parkinson’s disease , atypical parkinsonism and healthy controls. Material and methods: we included a total of 10 patients with early Parkinson’s disease, 11 patients with atypical parkinsonism and 10 healthy controls. Fractional anisotropy and mean diffusivity were measured, after obtaining conventional diffusionweighted magnetic resonance sequences. Results: fractional anisotropy in the caudate nucleus allowed to differentiate between patients with atypical parkinsonism group and the healthy control group. Mean diffusivity in the caudate nucleus allowed differentiation between the group of patients with atypical parkinsonism and healthy controls, as well as Parkinson’s disease group from healthy control group. Neither the fractional anisotropy or mean diffusivity in the targets chosen was able to differentiate between atypical parkinsonism and patients with early Parkinson’s. Conclusions: the magnetic resonance biomarkers used were only useful to discriminate healthy subjects from those with atypical parkinsonism or Parkinson’s disease.


REFERENCES

  1. Kessler I. Parkinson´s disease in epidemiologic perspective. Adv Neurol 1978;19:355-84.

  2. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson´s disease. A clinicopathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992;55:181-4.

  3. Brooks DJ, Pavese N. Imaging biomarkers in Parkinson´s disease. Prog Neurobiol 2011;95:614-28.

  4. Hu MT, White SJ, Herlihy AH, Chaudhuri KR, Hajnal JV, Brooks DJ. A comparison of (18) F-Dopa PET and inversion recovery MRI in the diagnosis of Parkinson´s disease. Neurol 2001; 56:1195-200.

  5. Hutchinson M, Raff U. Structural changes of the substantia nigra in Parkinson´s disease as revealed by MR imaging. AJNR Am J Neuroradiol 2000;21:697-701.

  6. Schrag A. Good CD, Miszkiel K, Morris HR, Mathias CJ, Lees Aj. Differentiation of atypical parkinsonian syndromes with rutine MRI. Neurol 2000;54:697-702.

  7. Schulz JB, Skalej M, Wedekind D, Luft AR. Magnetic resonance imaging- based volumetry differentiates idiopathic Parkinson’s syndrome from multiple system atrophy and progressive supranuclear palsy. Ann Neurol 1999;45:65-74.

  8. Seppi K, Schocke MF, Esterhamme R, Kremser C, Brenneis C, Mueller J. Dif fusion- weighted Imaging discriminates progressive supranuclear palsy from PD, but not from the Parkinson variant of multiple system atrophy. Neurol 2003; 60:922-7.

  9. Wei Zhang, Sheng GanSun, Yu-Hong Jiang. Determination of brain iron content in patients with Parkinson´s disease using magnetic susceptibility imaging. Neurosci Bull 2009;25:353-60.

  10. Hoehn M, Yahr M. Parkinsonism: onset, progression and mor tality. Neurol 1967;17:427-42.

  11. Gibb WR, Lees AJ. The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson’s disease. J Neurol Neurosurg Psychiatry 1988;51:745-52.

  12. Wenning GK, Colosimo C. Multiple system atrophy. Lancet Neurology 2004;3:93-103.

  13. Litvan I, Agid Y, Calne D, Campbell G, Dubois B, Duvosin RC. Clinical research criteria for the diagnosis of progressive supranuclear palsy: report of the NINDS-SPSP international workshops. Neurol 1996;47:1-9

  14. Fahn S, Marsden CD, Calne DB, Goldstein M, editors. Recent developments in Parkinson’s disease. Florham Park (NJ): Macmillan Health Care Information; 1987;(2)153-63,293-304.

  15. Wu Y, Le W, Jankovic J. Preclinical biomarkers of Parkinson disease. Arch Neurol 2011; 68:22-30.

  16. Hilker R, Schweitzer K, Coburger S, Ghamei M, Weisenbach S. Nonlinear progression of Parkinson disease as determined by serial positron emission tomographic imaging of striatal fluorodopa F 18 activity. Arch Neurol 2005; 62:378-82.

  17. Péran P, Cherubini A, Assogna F, Piras F, Quattrochi C, Peppe A. Magnetic resonance imaging markers of Parkinson´s disease nigrostriatal signature. Brain 2010;133:3423-33.




2020     |     www.medigraphic.com